Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) EBITDA (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of EBITDA data on record, last reported at -$20.9 million in Q1 2026.

  • On a quarterly basis, EBITDA rose 11.54% to -$20.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$107.7 million, a 35.22% decrease, with the full-year FY2025 number at -$110.4 million, down 40.06% from a year prior.
  • EBITDA reached -$20.9 million in Q1 2026 per RAPP's latest filing, up from -$33.4 million in the prior quarter.
  • Over the last five years, EBITDA for RAPP hit a ceiling of -$6.4 million in Q2 2023 and a floor of -$33.4 million in Q4 2025.
  • A 4-year average of -$19.9 million and a median of -$20.9 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 183.01% in 2024, then rose 11.54% in 2026.
  • Tracing RAPP's EBITDA over 4 years: stood at -$13.5 million in 2023, then plummeted by 54.66% to -$20.9 million in 2024, then tumbled by 59.61% to -$33.4 million in 2025, then soared by 37.33% to -$20.9 million in 2026.
  • Business Quant data shows EBITDA for RAPP at -$20.9 million in Q1 2026, -$33.4 million in Q4 2025, and -$26.7 million in Q3 2025.